These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 12067989)

  • 1. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF; Chen L; Zheng P; Liu Y
    Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
    Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
    Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.
    Lee J; Lee EN; Kim EY; Lee HJ; Park HJ; Sun CL; Lee SK; Joh JW; Lee KW; Kwon GY; Kim SJ
    Transplant Proc; 2005; 37(1):123-5. PubMed ID: 15808569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
    Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS
    Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
    Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
    Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
    Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy.
    Wilcox RA; Flies DB; Wang H; Tamada K; Johnson AJ; Pease LR; Rodriguez M; Guo Y; Chen L
    Cancer Res; 2002 Aug; 62(15):4413-8. PubMed ID: 12154048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.
    Melero I; Johnston JV; Shufford WW; Mittler RS; Chen L
    Cell Immunol; 1998 Dec; 190(2):167-72. PubMed ID: 9878117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.
    Vinay DS; Kwon BS
    Cell Immunol; 1999 Feb; 192(1):63-71. PubMed ID: 10066348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.
    Arribillaga L; Sarobe P; Arina A; Gorraiz M; Borrás-Cuesta F; Ruiz J; Prieto J; Chen L; Melero I; Lasarte JJ
    Vaccine; 2005 May; 23(27):3493-9. PubMed ID: 15855007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-1BB-mediated immunotherapy of rheumatoid arthritis.
    Seo SK; Choi JH; Kim YH; Kang WJ; Park HY; Suh JH; Choi BK; Vinay DS; Kwon BS
    Nat Med; 2004 Oct; 10(10):1088-94. PubMed ID: 15448685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
    Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
    Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen.
    Bai XF; Gao JX; Liu J; Wen J; Zheng P; Liu Y
    Cancer Res; 2001 Sep; 61(18):6860-7. PubMed ID: 11559562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.
    Choi BK; Kim YH; Kang WJ; Lee SK; Kim KH; Shin SM; Yokoyama WM; Kim TY; Kwon BS
    Cancer Res; 2007 Sep; 67(18):8891-9. PubMed ID: 17875731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
    J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
    Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
    Ellenhorn JD; Schreiber H; Bluestone JA
    J Immunol; 1990 Apr; 144(7):2840-6. PubMed ID: 1969454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.